This afternoon at #AACR26, visit LBPO.ET03 - Late-Breaking Research: Experimental and Molecular Therapeutics (Section 53) and see @KUcancercenter research in “First in class hSSB2 activator as a dual therapeutic strategy for overcoming RAS/MAPK inhibitor resistance while protecting normal epithelia in aggressive cancers” from 2-5pm PDT.